Shire & Baxalta Seal The Deal
Shire PLC and Baxalta Inc. shareholders have both voted in favor of the latter's sale to rare disease focused Shire for a price tag of $32bn – closing an almost year-long deal discussion.
Shire PLC and Baxalta Inc. shareholders have both voted in favor of the latter's sale to rare disease focused Shire for a price tag of $32bn – closing an almost year-long deal discussion.